GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » ROIC %

Assembly Biosciences (FRA:V7B) ROIC % : -108.82% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Assembly Biosciences's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -108.82%.

As of today (2024-05-27), Assembly Biosciences's WACC % is 9.64%. Assembly Biosciences's ROIC % is -273.32% (calculated using TTM income statement data). Assembly Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Assembly Biosciences ROIC % Historical Data

The historical data trend for Assembly Biosciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences ROIC % Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -161.25 -87.50 -161.37 -324.82 -233.08

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -680.66 -841.33 -827.10 -212.00 -108.82

Competitive Comparison of Assembly Biosciences's ROIC %

For the Biotechnology subindustry, Assembly Biosciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's ROIC % falls into.



Assembly Biosciences ROIC % Calculation

Assembly Biosciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-59.28 * ( 1 - -0.05% )/( (13.611 + 37.28)/ 2 )
=-59.30964/25.4455
=-233.08 %

where

Assembly Biosciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-39.484 * ( 1 - 0% )/( (37.28 + 35.289)/ 2 )
=-39.484/36.2845
=-108.82 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assembly Biosciences  (FRA:V7B) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Assembly Biosciences's WACC % is 9.64%. Assembly Biosciences's ROIC % is -273.32% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Assembly Biosciences ROIC % Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (FRA:V7B) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines